Equity Profile

DCTH

Delcath Systems, Inc.

Health CareHealth Care Equipment$372.1M

May5Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Delcath Systems, Inc. is a healthcare company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will look for any signs of revenue growth as it indicates the company's ability to expand its market presence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DCTH Q2-2026 Earnings Preview

Context

Company Snapshot

Delcath Systems, Inc. is a healthcare company focused on developing innovative treatments for cancer. They specialize in medical equipment that delivers targeted therapies to patients, which is increasingly important as the demand for effective cancer treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.79%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In the last quarter, Delcath reported an EPS of -$0.03, missing expectations. The stock reacted negatively, declining by 0.18% the next day.

Management Promises & Guidance

Management committed to focusing on advancing their product pipeline.
They emphasized the importance of upcoming clinical trials.
Management indicated they would work on improving operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations for Delcath's upcoming earnings report are mixed, given their recent performance and lack of analyst estimates.

Bull Case

If Delcath can show improved EPS and positive updates on their product pipeline, it could lead to increased investor confidence and a potential stock rally.

Bear Case

Conversely, if the company reports another earnings miss or fails to provide clear guidance on future growth, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be this quarter, and how does it compare to previous estimates?

The EPS will be a crucial indicator of the company's financial health and could heavily influence investor sentiment.

What updates will management provide on the product pipeline and upcoming clinical trials?

Any positive news on product development could drive future revenue growth and boost investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Delcath's product pipeline to deliver significant advancements this quarter.

Supporting Evidence

The company's recent focus on operational efficiencies could lead to better-than-expected results.

Historical trends show that the stock has reacted positively to unexpected product updates in the past.

Key Risk

If the product pipeline shows unexpected advancements or partnerships, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Delcath can demonstrate progress in profitability and product development.

Bull Confirmed If

A positive EPS surprise of $0.01 or better, along with optimistic updates on the product pipeline.

Bear Confirmed If

An EPS miss of $0.05 or worse, combined with a lack of clarity on future growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±17.0%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±17.0% while DCTH has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

42.6%

Calls (3K)P/C Ratio: 0.02Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Delcath beats expectations, history suggests a potential stock increase of around 5.82%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience a muted reaction as investors weigh future guidance.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 6.09%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the timelines for clinical trials.
2Details on any new partnerships or collaborations.
3Management's outlook on revenue growth for the upcoming quarters.
4Insights into operational improvements and cost management strategies.
5Any commentary on market trends affecting the healthcare equipment sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

DaVita Inc.

Company Snapshot

Delcath Systems, Inc. is a healthcare company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will look for any signs of revenue growth as it indicates the company's ability to expand its market presence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DCTH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.79%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In the last quarter, Delcath reported an EPS of -$0.03, missing expectations. The stock reacted negatively, declining by 0.18% the next day.

Management Promises & Guidance

Management committed to focusing on advancing their product pipeline.
They emphasized the importance of upcoming clinical trials.
Management indicated they would work on improving operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations for Delcath's upcoming earnings report are mixed, given their recent performance and lack of analyst estimates.

Bull Case

If Delcath can show improved EPS and positive updates on their product pipeline, it could lead to increased investor confidence and a potential stock rally.

Bear Case

Conversely, if the company reports another earnings miss or fails to provide clear guidance on future growth, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be this quarter, and how does it compare to previous estimates?

The EPS will be a crucial indicator of the company's financial health and could heavily influence investor sentiment.

What updates will management provide on the product pipeline and upcoming clinical trials?

Any positive news on product development could drive future revenue growth and boost investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Delcath's product pipeline to deliver significant advancements this quarter.

Supporting Evidence

The company's recent focus on operational efficiencies could lead to better-than-expected results.

Historical trends show that the stock has reacted positively to unexpected product updates in the past.

Key Risk

If the product pipeline shows unexpected advancements or partnerships, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Delcath can demonstrate progress in profitability and product development.

Bull Confirmed If

A positive EPS surprise of $0.01 or better, along with optimistic updates on the product pipeline.

Bear Confirmed If

An EPS miss of $0.05 or worse, combined with a lack of clarity on future growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±17.0%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±17.0% while DCTH has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

42.6%

Calls (3K)P/C Ratio: 0.02Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Delcath beats expectations, history suggests a potential stock increase of around 5.82%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience a muted reaction as investors weigh future guidance.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 6.09%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the timelines for clinical trials.
2Details on any new partnerships or collaborations.
3Management's outlook on revenue growth for the upcoming quarters.
4Insights into operational improvements and cost management strategies.
5Any commentary on market trends affecting the healthcare equipment sector.